AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14516883 — intervention group
Group type: COMPARATOR
Intervention: Exhaled CO in patients with cardiomyopathy at rest
Number of subjects: 37
Study 14516883 — intervention group
Group type: COMPARATOR
Intervention: Exhaled CO in patients with cardiomyopathy 1 minute after exercise
Number of subjects: 37
Study 14516883 — intervention group
Group type: COMPARATOR
Intervention: Exhaled CO in patients with cardiomyopathy 5 minutes after exercise
Number of subjects: 37
Study 14516883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled CO decrease in patients with cardiomyopathy after exercise
Number of subjects: 37
Study 14516883 — intervention group
Group type: COMPARATOR
Intervention: Exhaled NO in patients with cardiomyopathy at rest
Number of subjects: 37
Study 14516883 — intervention group
Group type: COMPARATOR
Intervention: Exhaled NO in patients with cardiomyopathy 1 minute after exercise
Number of subjects: 37
Study 14516883 — intervention group
Group type: COMPARATOR
Intervention: Exhaled NO in patients with cardiomyopathy 5 minutes after exercise
Number of subjects: 37
Study 14516883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exhaled NO increase in patients with cardiomyopathy after exercise
Number of subjects: 37
Study 10797781 — intervention group
Group type: EXPERIMENTAL
Intervention: Allevyn hydrocellular external application
Number of subjects: 3
Study 8911239 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol
Number of subjects: 24
Study 8911239 — intervention group
Group type: COMPARATOR
Intervention: H2 blockers
Number of subjects: 24
Study 1588630 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dosage methylprednisolone administered within 8 hours after injury
Number of subjects: 0
Study 1588630 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 3890730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g intravenously every 8 h)
Number of subjects: 21
Study 3890730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g intravenously every 8 h) + Piperacillin
Number of subjects: 21
Study 3890730 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g intravenously every 8 h) + Tobramycin
Number of subjects: 21
Study 30725362 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (18% of cohort, n = 115)
Number of subjects: 651
Study 29370865 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard meal
Number of subjects: 3
Study 29370865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 3
Study 29370865 — intervention group
Group type: COMPARATOR
Intervention: Fasting condition
Number of subjects: 3
Study 29370865 — intervention group
Group type: EXPERIMENTAL
Intervention: Food consumption
Number of subjects: 3
Study 27061709 — intervention group
Group type: COMPARATOR
Intervention: Specialist Supportive Clinical Management (SSCM)
Number of subjects: 142
Study 27061709 — intervention group
Group type: EXPERIMENTAL
Intervention: Maudsley Model of Anorexia Nervosa Treatment for Adults (MANTRA)
Number of subjects: 142
Study 27061709 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (SSCM and MANTRA)
Number of subjects: 142
Study 23759829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 167
Study 23759829 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study 22534136 — intervention group
Group type: EXPERIMENTAL
Intervention: Helical Tomotherapy (HT)
Number of subjects: 10
Study 20367114 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg IM dexketoprofen trometamol
Number of subjects: 70
Study 20367114 — intervention group
Group type: COMPARATOR
Intervention: 75 mg IM diclofenac sodium
Number of subjects: 70
Study 18630534 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking therapy (TCM plaster sticking at Zhongwan (CV 12), Guanyuan (CV 4), Qihai (CV 6))
Number of subjects: 108
Study 18630534 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture therapy (simple acupuncture at Zhongji (CV 3), Guanyuan (CV 4), Qihai (CV 6))
Number of subjects: 108
Study 16060181 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled rectal prolapse mucosectomy
Number of subjects: 100
Study 16060181 — intervention group
Group type: COMPARATOR
Intervention: Open hemorrhoidectomy
Number of subjects: 100
Study 12052586 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwave endometrial ablation
Number of subjects: 263
Study 12052586 — intervention group
Group type: COMPARATOR
Intervention: Transcervical endometrial resection
Number of subjects: 263
Study 12052586 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 263
Study 10325837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 100 mg
Number of subjects: 80
Study 10325837 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg
Number of subjects: 80
Study 10325837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 80
Study 10325837 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 80
Study 8621847 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine, 10 mg once daily
Number of subjects: 279
Study 8621847 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study 8621847 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine, 10 mg once daily
Number of subjects: 279
Study 1826243 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin (human ultralente insulin, n = 16)
Number of subjects: 35
Study 1826243 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprandial insulin (human unmodified insulin, n = 19)
Number of subjects: 35
Study 1826243 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 35
Study 6347356 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (DDP) alone, 70 mg/m2
Number of subjects: 109
Study 6347356 — intervention group
Group type: COMPARATOR
Intervention: Combination of cisplatin (DDP) and cyclophosphamide, initial dose of cyclophosphamide 750 mg/m2
Number of subjects: 109
Study 6347356 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 109
Study 6347356 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin (DDP) alone vs Combination therapy
Number of subjects: 109
Study 31701026 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial static magnetic field stimulation (tSMS) over the supplementary motor area (SMA)
Number of subjects: 0
Study 29536332 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation at a standard dose of 50 Gy in 25 fractions
Number of subjects: 60
Study 29536332 — intervention group
Group type: COMPARATOR
Intervention: Irradiation at a dose of 40.3 Gy in 13 fractions
Number of subjects: 60
Study 27529612 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 297
Study 27529612 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-linolenic acid
Number of subjects: 297
Study 27529612 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall n-6 fatty acids
Number of subjects: 297
Study 27529612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization and death events
Number of subjects: 297
Study 25207393 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-atlas segmentation with level set-based local search
Number of subjects: 0
Study 22480803 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/d duloxetine
Number of subjects: 30
Study 22480803 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/d duloxetine
Number of subjects: 30
Study 22480803 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20479938 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 DNA vaccine (VRC‐HVDNA 009‐00‐VP)
Number of subjects: 20
Study 20479938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 17653993 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy guided by musculoskeletal findings
Number of subjects: 22
Study 16055648 — intervention group
Group type: EXPERIMENTAL
Intervention: Thought focus manipulation in Euro-Canadians
Number of subjects: 0
Study 16055648 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive future events in Euro-Canadians
Number of subjects: 0
Study 16055648 — intervention group
Group type: COMPARATOR
Intervention: East Asians
Number of subjects: 0
Study 12403738 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly exercise class
Number of subjects: 93
Study 12403738 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise class)
Number of subjects: 93
Study 10434213 — intervention group
Group type: EXPERIMENTAL
Intervention: Nellcor pulse oximeter with Oxismart signal processing
Number of subjects: 53
Study 10434213 — intervention group
Group type: COMPARATOR
Intervention: Criticareaverage21s (signal averaging time set at 21 seconds)
Number of subjects: 53
Study 10434213 — intervention group
Group type: COMPARATOR
Intervention: Criticareaverage3s (signal averaging time set at 3 seconds)
Number of subjects: 53
Study 8846840 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 inhalation for 10 min
Number of subjects: 10
Study 8846840 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2 with air inhalation for 10 min
Number of subjects: 10
Study 2113543 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 2 mg)
Number of subjects: 23
Study 2113543 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 1.0 mg)
Number of subjects: 23
Study 2113543 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 2.0 mg)
Number of subjects: 23
Study 2113543 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 2113543 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (up to 1.0 mg after placebo)
Number of subjects: 23
Study 6250146 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (10 mg)
Number of subjects: 10
Study 6250146 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study 31303595 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral (oseltamivir) alone
Number of subjects: 329
Study 31303595 — intervention group
Group type: COMPARATOR
Intervention: Antiviral (oseltamivir) in combination with antibiotic
Number of subjects: 329
Study 28214095 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (15mg/kg/h)
Number of subjects: 40
Study 28214095 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 40
Study 25813217 — intervention group
Group type: COMPARATOR
Intervention: Avibactam 50, 100, 250, 500, 1000, 1500 or 2000 mg as a 30-min intravenous infusion (single ascending dose)
Number of subjects: 0
Study 25813217 — intervention group
Group type: EXPERIMENTAL
Intervention: Avibactam 250 mg with ceftazidime 1000 mg; Avibactam 500 mg with ceftazidime 2000 mg (second dose after washout)
Number of subjects: 0
Study 25813217 — intervention group
Group type: EXPERIMENTAL
Intervention: Avibactam 500, 750 or 1000 mg every 8 h over 5 days (multiple ascending doses)
Number of subjects: 0
Study 25813217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime-avibactam 2000-500 mg q8 h over 10 days
Number of subjects: 0
Study 25813217 — intervention group
Group type: EXPERIMENTAL
Intervention: Avibactam 500 mg (single oral dose)
Number of subjects: 0
Study 23660319 — intervention group
Group type: EXPERIMENTAL
Intervention: L + E (levodopa + entacapone)
Number of subjects: 240
Study 23660319 — intervention group
Group type: EXPERIMENTAL
Intervention: L (levodopa alone)
Number of subjects: 240
Study 23660319 — intervention group
Group type: EXPERIMENTAL
Intervention: L(−) (never on levodopa)
Number of subjects: 240
Study 23660319 — intervention group
Group type: COMPARATOR
Intervention: Control (people without PD or any other nervous system diseases)
Number of subjects: 240
Study 21412224 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg THC
Number of subjects: 14
Study 21412224 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg CBD
Number of subjects: 14
Study 21412224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19587369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification (LSM)
Number of subjects: 502
Study 19587369 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (MET)
Number of subjects: 502
Study 19587369 — intervention group
Group type: EXPERIMENTAL
Intervention: LSM plus MET
Number of subjects: 502
Study 19587369 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 502
Study 19587369 — intervention group
Group type: COMPARATOR
Intervention: Abnormal insulin resistance
Number of subjects: 502
Study 19587369 — intervention group
Group type: COMPARATOR
Intervention: Abnormal DeltaI/G
Number of subjects: 502
Study 19587369 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal beta-cell function with improved insulin sensitivity
Number of subjects: 502
Study 19587369 — intervention group
Group type: COMPARATOR
Intervention: Deterioration in both insulin resistance and beta-cell function
Number of subjects: 502
Study 17307037 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocking biopsy forceps
Number of subjects: 32
Study 17307037 — intervention group
Group type: COMPARATOR
Intervention: Standard biopsy forceps
Number of subjects: 32
Study 16422975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 10 mg
Number of subjects: 100
Study 16422975 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 100
Study 16422975 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 11565211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead STE (ST segment deviation in the single ECG lead of maximum ST deviation)
Number of subjects: 3593
Study 11565211 — intervention group
Group type: EXPERIMENTAL
Intervention: Sum STR (sum of ST segment elevation resolution)
Number of subjects: 3593
Study 11565211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead STR (ST segment resolution in the one lead showing maximal deviation)
Number of subjects: 3593
Study 11565211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lead STE
Number of subjects: 3593
Study 9817300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin combination chemotherapy
Number of subjects: 0
Study 9817300 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-chemotherapy resection for residual masses
Number of subjects: 0
Study 7875419 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil (35 micrograms, twice a day)
Number of subjects: 642
Study 7875419 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine (300 mg per day)
Number of subjects: 642
Study 7875419 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 642
Study 7875419 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 642
Study 2832102 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril 20 mg once daily
Number of subjects: 16
Study 2832102 — intervention group
Group type: EXPERIMENTAL
Intervention: atenolol 50 mg once daily
Number of subjects: 16
Study 2832102 — intervention group
Group type: EXPERIMENTAL
Intervention: enalapril plus atenolol
Number of subjects: 16
Study 2832102 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16
Study 28994661 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin D3 (120,000 IU/month)
Number of subjects: 51
Study 28994661 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose vitamin D3 (60,000 IU/month)
Number of subjects: 51
Study 28994661 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose vitamin D3 (18,000 IU/month)
Number of subjects: 51
Study 28807142 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (40, 80, 120, or 160 mg/d)
Number of subjects: 1527
Study 28807142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1527
Study 26336883 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii bowling intervention, played twice weekly for 6 weeks
Number of subjects: 0
Study 26336883 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 21761271 — intervention group
Group type: EXPERIMENTAL
Intervention: Original Hong Kong rule
Number of subjects: 148
Study 21761271 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified rule (age ≤ 55 years)
Number of subjects: 148
Study 21481649 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong Non Painful TENS
Number of subjects: 130
Study 21481649 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory Threshold TENS
Number of subjects: 130
Study 21481649 — intervention group
Group type: COMPARATOR
Intervention: Below Sensory Threshold TENS
Number of subjects: 130
Study 21481649 — intervention group
Group type: COMPARATOR
Intervention: No Current Placebo TENS
Number of subjects: 130
Study 21481649 — intervention group
Group type: COMPARATOR
Intervention: Transient Placebo TENS
Number of subjects: 130
Study 18308094 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 76
Study 18308094 — intervention group
Group type: COMPARATOR
Intervention: Photoselective vaporization (PVP)
Number of subjects: 76
Study 17885292 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPD + placebo
Number of subjects: 40
Study 17885292 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPD + MMF
Number of subjects: 40
Study 15531667 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond oil meal (30% energy from fat)
Number of subjects: 15
Study 15531667 — intervention group
Group type: EXPERIMENTAL
Intervention: Control meal (fat as oil, 30% energy from fat)
Number of subjects: 15
Study 15531667 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole almond meal (30% energy from fat)
Number of subjects: 15
Study 15531667 — intervention group
Group type: COMPARATOR
Intervention: Mixed-food test meals (all types)
Number of subjects: 15
Study 15531667 — intervention group
Group type: EXPERIMENTAL
Intervention: Almond oil meal, Control meal, Whole almond meal
Number of subjects: 15
Study 11177333 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin treatment before each meal plus a bedtime injection of ultralente insulin
Number of subjects: 26
Study 11177333 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled insulin treatment
Number of subjects: 26
Study 9046378 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 29
Study 9046378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 7712374 — intervention group
Group type: EXPERIMENTAL
Intervention: Moist ointment
Number of subjects: 115
Study 7712374 — intervention group
Group type: COMPARATOR
Intervention: 0.25% iodophor
Number of subjects: 115
Study 7712374 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine paste
Number of subjects: 115
Study 7712374 — intervention group
Group type: COMPARATOR
Intervention: 0.1% rivanol
Number of subjects: 115
Study 3331039 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem/cilastatin 1 g q 8 h
Number of subjects: 38
Study 3331039 — intervention group
Group type: COMPARATOR
Intervention: Aminoglycoside (tobramycin or netilmicin) plus amoxicillin 2 g q 8 h plus clindamycin 0.6 g q 6 h
Number of subjects: 38
Study 30146969 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive red‐cell transfusion strategy (transfusion if hemoglobin <7.5 g/dL)
Number of subjects: 5243
Study 30146969 — intervention group
Group type: COMPARATOR
Intervention: Liberal red‐cell transfusion strategy (transfusion if hemoglobin <9.5 g/dL in ICU or <8.5 g/dL in non-ICU)
Number of subjects: 5243
Study 30146969 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive red‐cell transfusion strategy
Number of subjects: 5243
Study 30146969 — intervention group
Group type: COMPARATOR
Intervention: Liberal red‐cell transfusion strategy
Number of subjects: 5243
Study 26522742 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise under Hypoxia (EHG)
Number of subjects: 40
Study 26522742 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise under Normoxia (ENG)
Number of subjects: 40
Study 26522742 — intervention group
Group type: COMPARATOR
Intervention: Hypoxia (HG)
Number of subjects: 40
Study 26522742 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (NG)
Number of subjects: 40
Study 25571209 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbend fiber sensor
Number of subjects: 22
Study 25571209 — intervention group
Group type: COMPARATOR
Intervention: Standard Polysomnography
Number of subjects: 22
Study 22316565 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation program (2 hours/week for six weeks)
Number of subjects: 71
Study 22316565 — intervention group
Group type: COMPARATOR
Intervention: Standard care and information (control group)
Number of subjects: 71
Study 20462392 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg montelukast (MK)
Number of subjects: 10
Study 20462392 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 10
Study 20462392 — intervention group
Group type: COMPARATOR
Intervention: Low PM PL
Number of subjects: 10
Study 20462392 — intervention group
Group type: EXPERIMENTAL
Intervention: Low PM MK
Number of subjects: 10
Study 20462392 — intervention group
Group type: EXPERIMENTAL
Intervention: High PM MK
Number of subjects: 10
Study 18615295 — intervention group
Group type: EXPERIMENTAL
Intervention: Exam room staffing (n = 120)
Number of subjects: 254
Study 18615295 — intervention group
Group type: COMPARATOR
Intervention: Conference room staffing (n = 134)
Number of subjects: 254
Study 18615295 — intervention group
Group type: EXPERIMENTAL
Intervention: Exam room staffing
Number of subjects: 254
Study 16042665 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI 5693 1125 mg
Number of subjects: 0
Study 16042665 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI 5693 300 mg
Number of subjects: 0
Study 16042665 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI 5693 750 mg
Number of subjects: 0
Study 16042665 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI 5693 with food intake (750 mg and 1125 mg)
Number of subjects: 0
Study 16042665 — intervention group
Group type: EXPERIMENTAL
Intervention: GPI 5693 300 mg, 750 mg, and 1125 mg
Number of subjects: 0
Study 12074820 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 71
Study 12074820 — intervention group
Group type: COMPARATOR
Intervention: Burch colposuspension (BC)
Number of subjects: 71